ARCHIVES

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Delays Decision On Avastin Approval For Breast Cancer

September 24, 2010

Group Opposes Bill To Allow Drug Sales After Phase I.

May 26, 2006

NSABP Protests NIH Rejection Of P-4 Appeal.

May 2, 2008

NCI’s Richard Kaplan named associate director, National Cancer Research Network of UK.

January 2, 2004

FDA Proposal To Regulate Tobacco Wins Support Of NCI, Oncology Societies

September 8, 1995

NIH Seeking Nominations for Review Committees

February 23, 1979